The Antibody Genetics of Multiple Sclerosis: Comparing Next-Generation Sequencing to Sanger Sequencing by William H. Rounds et al.
ORIGINAL RESEARCH ARTICLE
published: 16 September 2014
doi: 10.3389/fneur.2014.00166
The antibody genetics of multiple sclerosis: comparing
next-generation sequencing to Sanger sequencing
William H. Rounds1, Ann J. Ligocki 1, Mikhail K. Levin2, Benjamin M. Greenberg1, DouglasW. Bigwood 3,
Eric M. Eastman3, Lindsay G. Cowell 2 and Nancy L. Monson1,4*
1 Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, TX, USA
2 Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA
3 DioGenix Inc., Bethesda, MD, USA
4 Department of Immunology, University of Texas Southwestern Medical Center, Dallas, TX, USA
Edited by:
Amy Lovett-Racke, The Ohio State
University, USA
Reviewed by:
Mireia Guerau-de-Arellano, The Ohio
State University, USA
Helmut Butzkueven, University of
Melbourne, Australia
*Correspondence:
Nancy L. Monson, Department of
Neurology and Neurotherapeutics,
University of Texas Southwestern
Medical Center, 6000 Harry Hines
Blvd., NL9.110E, Dallas, TX
75390-8813, USA
e-mail: nancy.monson@
utsouthwestern.edu
We previously identified a distinct mutation pattern in the antibody genes of B cells iso-
lated from cerebrospinal fluid (CSF) that can identify patients who have relapsing-remitting
multiple sclerosis (RRMS) and patients with clinically isolated syndromes who will convert
to RRMS. This antibody gene signature (AGS) was developed using Sanger sequencing
of single B cells. While potentially helpful to patients, Sanger sequencing is not an assay
that can be practically deployed in clinical settings. In order to provide AGS evaluations
to patients as part of their diagnostic workup, we developed protocols to generate AGS
scores using next-generation DNA sequencing (NGS) on CSF-derived cell pellets without
the need to isolate single cells. This approach has the potential to increase the coverage
of the B-cell population being analyzed, reduce the time needed to generate AGS scores,
and may improve the overall performance of the AGS approach as a diagnostic test in the
future. However, no investigations have focused on whether NGS-based repertoires will
properly reflect antibody gene frequencies and somatic hypermutation patterns defined
by Sanger sequencing. To address this issue, we isolated paired CSF samples from eight
patients who either had MS or were at risk to develop MS. Here, we present data that
antibody gene frequencies and somatic hypermutation patterns are similar in Sanger and
NGS-based antibody repertoires from these paired CSF samples. In addition, AGS scores
derived from the NGS database correctly identified the patients who initially had or sub-
sequently converted to RRMS, with precision similar to that of the Sanger sequencing
approach. Further investigation of the utility of the AGS in predicting conversion to MS
using NGS-derived antibody repertoires in a larger cohort of patients is warranted.
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INTRODUCTION
Diagnosing diseases that affect the central nervous system (CNS) is
inherently challenging. Multiple sclerosis (MS) is an autoimmune-
mediated disease that exemplifies this challenge since clinicians
must use multiple diagnostic tools to obtain the required evidence
of dissemination of disease separated in time and space according
to the current McDonald criteria (1). This includes radiological
tests that detect lesions in the brain and spinal cord by mag-
netic resonance imaging (MRI) and is supported by biological
tests that detect a unique pattern of oligoclonal banding (OCB) in
the cerebrospinal fluid (CSF).
Due to the complexity associated with the current standard of
care for MS diagnosis, patients who suffer an initial acute onset of
“MS-like” symptoms [referred to as a clinically isolated syndrome
(CIS)] often have to wait before a diagnosis of MS is confirmed and
treatment is initiated (2). Steps to shorten this time frame are an
urgent matter in the field, considering that patients have a better
prognosis if treated early (3). Radiological testing (i.e., MRI) has
been instrumental in the diagnosis of MS, but the most frequently
used biological test that supports MS diagnosis is the OCB test,
which has relatively low diagnostic specificity when comparing
test performance for MS vs. other neuro-inflammatory diseases
(about 61%) (4–6).
The standardization of the OCB test to support an MS diagnosis
led many neuroimmunologists in the field to focus on determin-
ing the role of B cells and their antibodies on the pathogenesis
of MS (7–11). Early work by our group and others demon-
strated that CSF-derived B cells from MS patients and CIS patients
that convert to MS undergo extensive clonal expansion, skew-
ing toward heavy chains of the fourth family, and accumulate
somatic hypermutations (SHM) at an advanced rate (12–14).
These features of antibody genetics are suggestive of a hyper-
response to CNS antigens, but the targets of these CSF-derived
B cells from MS patients remain elusive (15). More recently,
however, our laboratory has discovered that the fourth fam-
ily of heavy-chain antibody genes of CSF-derived B cells from
MS patients accumulates replacement mutations at six codon
positions more frequently than patients with other neurologi-
cal diseases (OND) (16). B cells in MS lesions also display this
pattern (17).
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Using a custom algorithm to indicate the extent of mutation
accumulation at these six codons in antibody gene repertoires, we
developed a new biological test called the antibody gene signa-
ture (AGS), which demonstrated promise in a small pilot cohort
in identifying patients who had one demyelinating event and who
would convert to MS (16). However, these initial studies on the
utility of AGS were based on Sanger sequencing, which is too labo-
rious and expensive for routine use if this technology is developed
as a clinical diagnostic test for MS in the future.
Next-generation DNA sequencing (NGS) might potentially
provide a useful alternative in acquiring antibody gene repertoires
to use for AGS calculations and is becoming routine in the field
as evidenced by its commercial availability as a fee for service
(Life Technologies, Illumina, and Seqwright among many others).
The most common application of NGS to antibody genetics has
focused on VDJ recombination gene selection for the purpose of
analyzing lymphocyte clonality (18–21), and is now being utilized
in the MS field (22). Since gene and SHM distributions are at the
core of antibody genetics analysis (as well as AGS scoring), careful
scrutiny of this platform and its ability to properly represent the
antibody gene repertoire is warranted.
Our primary goal was to provide confirmation that the anti-
body gene repertoires generated by NGS would sufficiently rep-
resent the CSF-derived B-cell pool from MS patients. The data
presented here demonstrate for the first time that antibody gene
repertoires from individual CSF-derived B cells from the CSF of
MS patients and those at high risk to convert, generated by the gold
standard Sanger method, are reliably reflected in NGS-generated
antibody gene repertoires from paired CSF-derived B-cell pools
of the same patients. Furthermore, we confirmed that AGS scor-
ing, generated using a high-throughput NGS approach of pooled
CSF cells, also identified MS patients and those that would convert
to MS with the same accuracy as AGS scoring using Sanger DNA
sequencing of individual CSF B cells. This NGS approach provides
a new method for measuring the biological changes observed in
MS patients and demonstrates its potential as a diagnostic tool.
MATERIALS AND METHODS
MS/CIS PATIENT DESCRIPTION AND CSF SAMPLE PREPARATION
Cerebrospinal fluid B cells from six CIS and two relapsing-
remitting multiple sclerosis (RRMS) patients were used for this
paired analysis. All CSF samples were collected in accordance
with a protocol approved by the UT Southwestern Medical Cen-
ter (UTSWMC) Institutional Review Board (IRB). CSF samples
selected for comparative analysis were collected from eight patients
who were either diagnosed with RRMS or CIS at the time of collec-
tion or who were subsequently diagnosed with RRMS (Table 1).
Single CD19+ B cells were sorted into individual wells of a 96-
well microtiter plate for single-cell Sanger DNA sequencing. At
the same time, a pool of sorted CD19+ B cells from each patient
was collected for NGS analysis. One pooled B-cell sample (C8) did
not produce a detectable PCR product after nested PCR and thus
was removed from the NGS cohort.
NEXT-GENERATION SEQUENCING CONTROLS
Naïve (CD19+ CD27−) and memory (CD19+ CD27+) periph-
eral blood B-cell pools were isolated from three healthy control
samples and used as process controls to evaluate batch to batch
variation and to aid in the evaluation of potential sequence
errors generated during processing. Peripheral blood from healthy
control donors was collected in blood tubes containing heparin
as an anti-coagulant (BD, Franklin Lakes, NJ, USA). Peripheral
blood mononuclear cells (PBMCs) were isolated by centrifuga-
tion through Ficoll-Paque (GE Healthcare, PA, USA). PBMCs were
washed, counted, and stained before being used to isolate naïve
and memory B cells as described previously (23). The naïve NGS
sequences had average nucleotide mutation frequencies (MF) of
1.3% and average replacement mutation frequencies (RMF) of
1.4% for over 10,000 sequences, thus indicating low frequency of
mutation errors due to PCR amplification and NGS sequencing.
The memory NGS sequences had average MFs of 8.7% and aver-
age RMFs of 17.7% for roughly 3,700 sequences, which is similar
to Sanger sequencing calculations (24). Previous work examining
base-specific error rates identified a skewing toward the follow-
ing order: A≥T>G>C (25) in sequences that had been PCR
amplified prior to NGS. We also observe an overall increase in
A and decrease in G mutations in the paired samples as expected
from this earlier work, even though we used a different polymerase
for PCR amplification (we used Phusion High-fidelity DNA poly-
merase from New England Biolabs, while Shao and colleagues
used Hi Fidelity Platinum Taq from Invitrogen) (Figure S1 in
Supplementary Material).
SINGLE B-CELL RECEPTOR DATABASE GENERATION USING SANGER
DNA SEQUENCING
Sanger fourth family of variable heavy-chain region (VH4)
sequence databases were generated at UTSWMC by nested PCR of
single-sorted CD19+ CSF B cells using degenerate PCR primers,
Taq DNA Polymerase (Promega, Madison, WI, USA), and Sanger
DNA sequencing as previously described (12, 26, 27).
PCR OF ANTIBODY GENES FROM CSF-DERIVED B-CELL POOLS
Details of this method are provided in the Supplementary Mater-
ial. All PCR reactions were performed using Phusion High-fidelity
DNA polymerase (New England Biolabs, Ipswich, MA, USA) to
minimize amplification errors.
NEXT-GENERATION SEQUENCING OF CSF-DERIVED B-CELL POOLS
Details of this method are provided in the Supplementary Mate-
rial. Sequencing was done on the 454 GS FLX DNA Sequencer
using the 454 Titanium chemistry (Roche/454, Branford, CT, USA)
according to the manufacturer’s recommended protocols.
NGS 454 DATA PROCESSING
Details of this method are provided in the Supplementary Mate-
rial. In total, we analyzed 212 Sanger-generated sequences from
single B cells and 16,984 unique NGS-generated sequences. Sanger
sequencing produced an average of 30 unique VH4 sequences per
patient, although fewer than 20 sequences were obtained from
three of the patients (C1, C4, and C7) (Table 2). Although NGS
sequencing produced an average of 2,426 unique VH4 sequences
per patient, fewer than 1,000 sequences were obtained from two of
the patients (C3 and C4) and one of these patients only yielded 14
unique VH4 sequences. The large number of unique sequences in
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Table 1 | Patient sample summary.
Patient
ID
Initial
diagnosisa
OCB
status
Comments Follow-up
diagnosisb
Follow-up
timec
Aged Gender Sanger
AGS
NGS
AGS
C1 CIS NEG High risk of RRMS CIS 44 45 F 6.43 13.32
C2 CIS POS Single lesione CIS 26 34 F 13.07 4.43
C3 CIS POS RRMS 1 39 F 10.47 13.88
C4 CIS POS High risk of RRMS RRMS 8 27 F 17.90 17.55
C5 RRMS POS On steroids RRMS 36 19 F 16.73 8.21
C6 RRMS POS RRMS 25 19 F 17.62 10.26
C7 CIS POS High risk of RRMS RRMS 31 33 M 22.26 18.01
C8 CIS POS Low risk of RRMS RRMS 8 34 F 10.17 NA
Initial diagnosis at the time of sample collection is indicated for each patient in the study.
OCB, oligoclonal bands; AGS, antibody gene signature; CIS, clinically isolated syndrome; RRMS, relapsing-remitting multiple sclerosis.
aAt time of sampling using 2005 McDonald criteria.
bUsing 2010 McDonald criteria.
cSince sampling (months).
dAt time of sampling (years).
eBy MRI of the brain.
Table 2 | Sequence database size summary.
Patient
ID
No. of Sanger
VH4 sequences
No. of B cells
in cell pellet
for NGS
No. of unique
NGSVH4
sequences
C1 7 29 2,475
C2 41 100 2,213
C3 61 100 14
C4 14 30 596
C5 25 100 5,020
C6 46 100 4,290
C7 18 100 2,376
Average 30 2,426
For each patient, the initial VH4 sequences obtained by Sanger sequencing of
single B cells, the number of B cells in the cell pellet used for NGS PCR and
sequencing, and the number of unique VH4 NGS sequences after filtering are
indicated. Of note, a typical Sanger-based antibody repertoire can take several
months to generate, whereas NGS-based repertoires can take as little as 1 week.
the NGS database relative to the number of B cells in the cell pellet
is a consequence of the accumulation of PCR- and NGS-generated
errors in the sequence database. Our focus here is to examine how
well the sequence characteristics of the original patient template
pools are maintained through NGS sequencing by comparing the
patient’s Sanger database.
MUTATION ANALYSES
Sequence and mutation information was available and calculated
from Chothia codons 31–92 (28, 29). This region includes com-
plementarity determining region (CDR) 1 through framework
regions (FR) 3 as originally defined by Kabat (30). Analyses were
done for both nucleotide mutation frequency (MF) and amino
acid RMF. CDR and FR region mutation data were obtained by
separating mutations in CDR1 and CDR2 from those in FR2 and
FR3 and normalizing based on the lengths of the specific region.
At the codon level, mutations were characterized as either
replacement or silent mutations (RM or SM) and R:S ratios were
calculated as RM divided by SM. AGS scores were calculated as
previously described: they are the sum for each AGS codon (31b;
40; 56; 57; 81; 89) of [RMF at the AGS codon minus the average
RMF (1.6) in a healthy control peripheral blood database divided
by the standard deviation (0.9) of the average RMF of the same
healthy control database] (16). Patients with AGS scores above 6.8
are identified as “RRMS.”
STATISTICAL ANALYSES
VH4 and JH gene frequencies, mutated nucleotide frequencies,
and AGS-contributing codon frequencies were grouped by plat-
form and compared by Chi-squared analysis. MF, R:S ratios, and
AGS scores were evaluated as patient-specific data points and
their distributions between platforms were compared by Wilcoxon
matched-pairs signed rank test. Statistical significance for all meth-
ods was attributed to p-values≤0.05. Using the follow-up diagno-
sis as the basis for evaluation, specificity, sensitivity, and accuracy
were calculated for OCB, Sanger AGS, and NGS AGS. Specificity
was calculated as (no. of correct CIS assessments)/(no. of CIS
samples); sensitivity was calculated as (no. of correct RRMS assess-
ments)/(no. of RRMS samples); and accuracy was calculated as
(no. of correct assessments)/(no. of samples).
RESULTS
Sanger sequencing has been the gold standard to define the anti-
body repertoires of patients with autoimmune diseases such as MS
(26, 31–37). Such findings have provided necessary information to
further our understanding on the role of B cells and their antibody
products on the pathology of MS, the application of new targeting
therapeutics, and the development of new diagnostic tools. NGS
represents an advanced sequencing method to query even massive
B-cell pools, and has already been applied to defining B-cell clonal-
ity in MS patients (22). However, it is critical to evaluate whether
this new sequencing technology properly represents the unique
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features that were previously established by Sanger sequencing for
antibody genetics in B cells from the CSF of MS patients.
Thus, we compared the antibody gene repertoires generated
from single CSF-derived B cells using Sanger sequencing and
those generated from CSF B-cell pools using NGS in a cohort
of MS/CIS patients. There were significant differences in the fre-
quency of individual VH4 gene usage between the platforms,
although the relative abundance of individual VH4 gene seg-
ments by rank was globally consistent (Figure 1A). In the com-
parison of the Sanger and NGS databases, VH4-30, VH4-34,
and VH4-39 sequences show significant differences in abun-
dance. VH4-39 was the most abundant gene segment in the
Sanger database, but is the third most abundant gene segment
in the NGS database. All the other VH4 gene segments remain
in the same ranked order of abundance in both databases. The
rank order of the VH4-b, VH4-4, and VH4-61 gene segments
do not significantly vary between platforms. VH4-59 has a sig-
nificant increase in NGS (15–24%; p= 0.004), which does not
alter its rank. One noticeable difference is the lower abundance
of long VH4 gene segments (VH4-30, VH4-31, VH4-39, and
VH4-61) in the NGS database (23%) compared with the Sanger
database (54%).
JH usage is important because skewing from the normal distrib-
ution of dominant JH4 usage (38) can be evidence of self-reactivity
(39). JH4 remained the most abundant gene segment in both the
Sanger and NGS databases (compare 38–40%; p= 0.53) and JH3
remained the fourth most abundant gene segment in both data-
bases (compare 11–9%; p= 0.18) (Figure 1B). JH5 and JH6 were
significantly decreased in the NGS database, whereas JH1 and JH2
were significantly increased and resulted in significant differences
in frequencies of these four JH genes between the platforms.
Skewing of mutation frequency and/or placement of mutations
in antibody genes from the CSF of MS patients is well established
(12–14, 26). It is important, therefore, that the identification of
the mutation accumulation and distribution is similar regardless
of the platform by which it was generated. With regard to the accu-
mulation of mutations, the overall nucleotide MF for individual
patients by Sanger and NGS were similar (5.4–7.1%; p= 0.16)
(Figure 2A; Table S1 in Supplementary Material). The RMF was
also consistent between platforms (Figure 2B; Table S1 in Supple-
mentary Material), again with a non-significant increase in NGS
(9.7–12.5%; p= 0.11). With regard to the distribution of muta-
tions, the MF and RMF were also appropriately highest in the
CDRs, which are the antigen-contacting sites. The FRs, which are
the structural support regions of the antibody genes, had rela-
tively few MF and RMF accumulations as expected (Figures 2A,B).
The replacement to silent mutation ratios (R:S ratios) in the CDR
regions increase from patient to patient (average 4.4–7.3; p= 0.58)
in the NGS platform, but without a significant trend emerging
(Figure 2B). The R:S ratios in the FR regions were not significantly
altered across platforms (1.4–1.5; p= 0.94).
Antibody gene signature scoring by Sanger sequencing showed
initial success on a pilot cohort in identifying MS patients or
CIS patients who will convert to MS (16), which has been con-
firmed in larger sample cohorts (Figure 3A). To understand how
antibody repertoire generation by NGS might affect AGS scoring
calculations, we analyzed and compared the RMF at each codon
FIGURE 1 |VH4 gene distributions show cross-platform variation for
samples from both patients with RRMS and CIS. VH4 (A) and JH (B)
gene calls were obtained by IMGT alignment. Total sequences used in
Sanger sequencing and next-generation sequencing (NGS) databases are
indicated inside the pie charts. Statistically significant differences between
the frequencies of individual genes were identified by Chi-squared test
(p-value: N.S. ≥0.05).
FIGURE 2 | Mutation characteristics ofVH4 sequences in RRMS and
CIS patients are shown. Sanger sequence data include 212 sequences
with 2265 total point mutations and 1386 total replacement mutations
(RM). Next-generation sequencing (NGS) data include 16,984 unique
sequences with 263,764 total point mutations and 154,457 total
replacement mutations (RM). (A) Mutation frequency (MF) analysis was
done by nucleotide; (B) replacement mutation frequencies (RMF) analysis
was done by codon. MF and RMF were calculated by patient, and bar
graphs show mean (indicated on the bar graphs) and S.D. (statistical
significance of the distributions was tested for by Wilcoxon matched-pairs
signed rank test; N.S. ≥0.05). MF, RMF, and R:S ratios for CDR and FR
regions were calculated independently by region for each patient and are
shown as patient means.
position that defines the AGS (Figure 3B). Only codons 56 and
57 of the AGS maintained similar RMF to the Sanger repertoires.
RMF at codons 40 and 89 were significantly increased and RMF at
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FIGURE 3 | Antibody gene signature (AGS) in RRMS and CIS patients is
shown. (A) Unpaired Sanger sequence datasets for multiple sclerosis (MS,
includes relapsing-remitting, primary and secondary progressive MS samples)
and other neurological disease (OND) cohorts. Each data point represents a
single patient sequence pool that was not analyzed by NGS. The dotted line
represents the AGS cut-off point of 6.8 above which patients are expected to
convert to relapsing-remitting multiple sclerosis (RRMS). Mean and standard
deviation are shown. (B) Replacement mutation frequencies (RMF) of each of
the six AGS codons were calculated relative to the total AGS RM in each
dataset. P -values were calculated by Chi-squared test. (C) Each data point
represents a single patient sequence pool. The dotted line represents the AGS
cut-off point of 6.8 above which patients are expected to convert to RRMS.
Mean and standard deviation are shown. Statistical significance of the
distributions was tested for by Wilcoxon matched-pairs signed rank test (N.S.
≥0.05). (D)The AGS scores of the seven paired patients are shown here.
(E)The percent of total RMs that belong to the AGS pattern in each sequence
was mapped for three patients with different types of AGS score shifts from
one platform to another. The boxes indicate mean and the error bars S.D.
codons 31B and 81 were significantly decreased in comparison to
the Sanger repertoires.
Despite these fluctuations in mutation distributions among the
six AGS codons, we observed a non-significant change (14.9–12.2;
p= 0.22) in the paired samples of the average AGS score with the
NGS platform (Figure 3C) (16). Two patients who have not yet
received a confirmed RRMS diagnosis (patients C1 and C2) did
not have consistent AGS scores between the Sanger and NGS data-
bases (Figure 3D). However, all of those patients who did have
RRMS or converted to RRMS after sampling showed consistent
classification of disease by both Sanger sequencing and NGS. In
addition, the specificity (50%), sensitivity (100%), and accuracy
(85.7%) of properly identifying patients that have MS or would
convert to MS in the future in this small cohort was the same for
NGS-based, Sanger-based, and OCB biological testing. However,
the small size of the cohort precludes any conclusion regarding the
utility of NGS-based AGS scoring as a viable diagnostic test.
Finally, to understand these fluctuations in AGS scores between
the two platforms, we show the distribution of AGS codon RM
frequency and how it affects AGS scores for three representa-
tive samples. For example, in the Sanger repertoire of patient
C2, approximately 21% of all RMs are within the AGS codons
(Figure 3E) resulting in an AGS score of 13.07. In the NGS reper-
toire of this same patient, only 14% of all RMs are within the AGS
codons resulting in a decreased AGS score of 4.43. Conversely, the
NGS repertoire of patient C1 had an increased AGS score com-
pared to the Sanger repertoire because of an increased percentage
of RMs in AGS codons relative to all codons (compare 15% in
Sanger vs. 22% in NGS). Patient C4 had similar percentages of
RM in AGS codons on both platforms (26 vs. 25%), and thus had
similar AGS scores on both platforms (17.90 vs. 17.55%).
DISCUSSION
Radiological testing to support MS diagnosis has excelled and is
indispensable in the diagnosis of MS, whereas development of
biological tests to support MS diagnosis has been more chal-
lenging. One type of biological testing that is on the horizon is
next-generation DNA sequencing (NGS), which can be used to
query the antibody genetics of even massive B-cell pools (18–22).
Historically, this technology has been very successful in tracking
minimal residual disease in cancer patients (18). More recently,
the power of this technology has been used to demonstrate that
focused B-cell clones in the CSF of MS patients are identifiable in
the vast peripheral B-cell pools of the same patients (22). Thus,
the use of NGS to pursue biological questions in MS has become
a reality.
Our goal for this study was to advance beyond clonality queries
and address whether the features of antibody genetics that we had
observed in CSF-derived B cells from MS patients with regard
to antibody gene distribution (i.e., skewing toward VH4 fam-
ily usage) and somatic hypermutation accumulation (i.e., AGS)
could be confirmed using this deeper sequencing method. This
is important because NGS is now readily available commercially,
and its possible limitations must be understood to best translate
the information that we obtain from it. To do this, we compared
paired antibody repertoires generated from single CSF-derived B
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cells using Sanger sequencing and antibody repertoires generated
from CSF B-cell pools using NGS. This is the first time that there
has been a direct comparison of this new technology to Sanger
sequencing, which is the gold standard in the field.
Overall, we found that NGS and Sanger sequence data were
similar with regard to general mutational profiles but differed
somewhat in the distribution of VH4 sub-family members recov-
ered. Due to the similarity between the sequences of the VH4
sub-family gene segments, the divergence inVH4 distribution may
be partially due to an increase in sequencing errors in the NGS
database, the most common of which is insertion and deletion
(indel) errors, particularly in regions that contain homopolymers
or stretches containing two or more identical nucleotides (40).
The reported frequency of indels generated by the Roche/454 plat-
form is in the range of 3.8 to 5× 10−3 (41, 42). Indels are easily
detected by alignment of NGS-generated sequences to published
VH4 sequences using the IMGT/High V-Quest tool (43). Since we
remove all non-productive (with stop codons or frameshift muta-
tions) or misaligned (<85% homology) antibody sequences, our
NGS databases should contain very few sequences with indels. In
order for a sequence with indels to pass our filters, they would
have to contain multiple complementary indel events in close
proximity – an extremely unlikely scenario. Nucleotide substitu-
tion errors can also occur (44), but we used a very high-fidelity
DNA polymerase to generate our NGS-based antibody repertoires
so that the MF between the Sanger and NGS databases would be
similar.
All five patients who had or converted to RRMS were prop-
erly identified using our AGS biological test method by Sanger
sequencing or NGS. There was some fluctuation in the AGS scores
obtained for these paired samples between the two platforms,
which could be due to a decreased representation in NGS of the
long VH4 genes that contain codon 31b. The AGS scoring system
is based on MF at six codons, which includes 31b. Thus, if genes
containing 31b are not properly represented in the NGS reper-
toire database in comparison to Sanger database, a decrease in
AGS scores would be a natural consequence. Despite these differ-
ences in Sanger and NGS repertoire generation, identification of
MS patients or CIS patients that would convert to MS remained
the same between the two platforms.
The two CIS patients who did not convert to RRMS at follow-
up are representative of biological testing complications due to
patient care received. CIS patient C1 was at high risk to develop
MS. The Sanger-based AGS score was below the 6.8 cut-off point,
but the NGS-based AGS score was above the cut-off point sug-
gesting that this patient would convert to RRMS in the future.
CIS patient C2 was OCB positive at the time of sampling, with
a single brain lesion noted by MRI, and was thus considered
at low risk to develop MS. The Sanger-based AGS score was
above the 6.8 cut-off point, but the NGS-based AGS score was
below the cut-off point. In both of these cases, the patients
were placed on disease modifying therapy shortly after sampling,
making it difficult to determine what the natural progression of
their demyelinating event may have been. Of note, patient C5
who was on steroids at the time of sampling and converted to
RRMS had an AGS score above the 6.8 cut-off point by both
platforms.
This study suggests that the transition from single B-cell Sanger
sequencing to high-throughput NGS of pooled B cells is feasible
with the application of appropriate sequence filtering methods to
efficiently remove sequences containing errors generated during
sample processing and sequencing. The implementation of appro-
priate quality metrics to identify and remove as many process-
generated errors as possible will be critical for the successful use
of NGS to better understand the antibody genetics of MS and for
the future development of a clinically useful NGS diagnostic test
based on the AGS scoring algorithm. These results will need to be
confirmed in a larger cohort of patients using NGS-based antibody
repertoire generation before consideration as a diagnostic tool can
be made.
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